

Dkt. No. 60326/PJP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Carolyn E. Mountford et al.

Serial No.

09/691,776

Group Art Unit: 3737

Filed

October 18, 2000

For

MAGNETIC RESONANCE SPECTROSCOPY OF BREAST

BIOPSY TO DETERMINE PATHOLOGY, VASCULARIZATION

AND NODAL INVOLVEMENT

1185 Avenue of the Ame New York, New York 100 July 11, 2003

Commissioner for Patents' P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following attached references, which are listed on the accompanying form PTO-1449 (Exhibit 1).

1. Kitchen PR, McLennan R, Mursell A. Node-positive breast cancer: a comparison of clinical and pathological findings and assessment of axillary clearance. Australian & New Zealand Journal of Surgery 1980; 50:580-3.

09/05/2003 NLAWRENC 00000002 033125 09691776

01 FC:1806 180.00 DA

Dixon JM, Senbanjo RO, Anderson TJ, mammography. Risk of breast cancer based on age and mammographic interpretation [JAMA 1996; 276:39-43].

Applicants Serial No. Filed Page 2 Carolyn E. Mountford et al.

09/691,776

October 18, 2000

6. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE. Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magnetic Resonance in Medicine 1993; 30:525-33.

- 10. Somorjai RL, Dolenko B, Nikulin AK, et al. Classification of 1H MR spectra of human brain neoplasms: the influence of preprocessing and computerized consensus diagnosis on classification accuracy. Journal of Magnetic Resonance Imaging 1996; 6:437-44.
- 13. Weidner N. Prognostic factors in breast carcinoma. Current Opinion in Obstetrics & Gynecology 1995; 7:4-9.
- 18. Beechey-Newman N. Sentinel node biopsy: a revolution in the surgical management of breast cancer? Cancer Treatment Reviews 1998; 24:185-203.
- 23. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994; 24:41-7.

Applicant believes that the cited art does not anticipate or render obvious applicant's claimed invention.

This Suplemental Information Disclosure Statement supplements the Information Disclosure Statement submitted June 13, 2003 as part of an Amendment. A fee of \$180 was submitted with the Amendment for the Information Disclosure Statement. Accordingly, no fee is

Applicants Serial No. Filed Page 3

Carolyn E. Mountford et al.

09/691,776

October 18, 2000

believed to be necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

In the event that a Notice of Allowance has been mailed, applicant hereby petitions, pursuant to 37 C.F.R. \$1.97(d), for consideration Supplemental Information Disclosure Statement, authorize the Office to charge Deposit Account No. 03-3125 the amount of the fee in accordance with 37 C.F.R. §1.17(i).

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexamdria,

Odern.
J. Phillips

Reg. No. 29,691

Peter J. Phillips

Registration No. 29,691 Attorneys for Applicants

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

(212) 278-0400